

Preventive screenings

Osteoporosis Management In Women Who Had a Fracture (OMW)

Osteoporosis Management In Women Who Had a Fracture (OMW) Measure year 25 | Weight = 1

Measurement period

July 1 of prior year to June 30 of the measure year

Eligible population

Women 67–85 years of age who suffered a fracture (face, skull, fingers or toes are excluded) who suffered a fracture between July 1 of the prior year and June 30 of the current measure year.

Service needed for compliance

- A bone mineral density (BMD) test in any setting and/or
- The patient is dispensed osteoporosis medication or therapy, including long-acting osteoporosis therapy provided during inpatient stay for fracture

Service is needed within six months (180 days)

- Of fracture date or
- Discharge date if hospitalized for fracture

Exclusions

- Patients in hospice, using hospice services or receiving palliative care anytime during the measure year
- Patients who died anytime during the measurement year
- Patients 67–85 years of age living long-term in an institutional setting or are enrolled in an Institutional Special Needs Plan (I-SNP)
- Patients 67–80 years of age with both frailty (at least two indications) and advanced illness (at least two different dates of service or dispensed dementia medication)
- Patients 81–85 years of age with frailty only (with at least two indications of [frailty](#))

Patients are also removed from eligibility with evidence of the following:

- BMD test within 24 months prior to the fracture
- Dispensed or active prescription to treat or prevent osteoporosis within the 12 months prior to the fracture
- Osteoporosis therapy within 12 months prior to the fracture

Note: For MY24, supplemental data cannot be used to provide information regarding clinical events that should exclude patients from the OMW denominator due to a change in the technical specifications. Supplemental data can still be used for numerator compliance. Centers for Medicare & Medicaid Services (CMS) is reviewing this issue for a possible adjustment in MY25.

Measure best practices

- Discuss with patient the option to prescribe Food and Drug Administration (FDA)-approved medications and discuss lifestyle changes to treat or prevent osteoporosis (such as exercise, vitamins, mineral supplements) or for them to complete a BMD test.
- For new patients, obtain medical records and look for evidence of a BMD test 24 months prior to the fracture or evidence of conditions that would exclude a patient from the measure.
- When documenting medication or test, ensure proper documentation of the specifics in the medical record (test date and finding, medication name, dispense date, dosage/strength and administration route) and submit as supplemental data.

Healthcare Effectiveness Data and Information Set (HEDIS®)

Code	Code type	Definition
76977	Current Procedural Terminology (CPT®)	Ultrasound bone density measurement and interpretation, peripheral site(s), any method
77078	CPT	Computed tomography, bone mineral density study, one or more sites; axial skeleton (e.g., hips, pelvis, spine)
77080	CPT	Dual-energy X-ray absorptiometry (DXA), bone density study, one or more sites; axial skeleton (e.g., hips, pelvis, spine)
77081	CPT	Dual-energy X-ray absorptiometry (DXA), bone density study, one or more sites; appendicular skeleton (peripheral) (e.g., radius, wrist, heel)
77085	CPT	Dual-energy X-ray absorptiometry (DXA), bone density study, one or more sites axial skeleton (e.g., hips, pelvis, spine), including vertebral fracture assessment
77086	CPT	Vertebral fracture assessment via dual-energy X-ray absorptiometry (DXA)
BP48ZZ1	International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS)	Ultrasonography of right shoulder, densitometry
BP49ZZ1	ICD-10-PCS	Ultrasonography of left shoulder, densitometry
BP4GZZ1	ICD-10-PCS	Ultrasonography of right elbow, densitometry
BP4HZZ1	ICD-10-PCS	Ultrasonography of left elbow, densitometry
BP4LZZ1	ICD-10-PCS	Ultrasonography of right wrist, densitometry
BP4MZZ1	ICD-10-PCS	Ultrasonography of left wrist, densitometry
BP4NZZ1	ICD-10-PCS	Ultrasonography of right hand, densitometry
BP4PZZ1	ICD-10-PCS	Ultrasonography of left hand, densitometry
BQ00ZZ1	ICD-10-PCS	Plain radiography of right hip, densitometry
BQ01ZZ1	ICD-10-PCS	Plain radiography of left hip, densitometry
BQ03ZZ1	ICD-10-PCS	Plain radiography of right femur, densitometry
BQ04ZZ1	ICD-10-PCS	Plain radiography of left femur, densitometry
BR00ZZ1	ICD-10-PCS	Plain radiography of cervical spine, densitometry
BR07ZZ1	ICD-10-PCS	Plain radiography of thoracic spine, densitometry
BR09ZZ1	ICD-10-PCS	Plain radiography of lumbar spine, densitometry
BR0GZZ1	ICD-10-PCS	Plain radiography of whole spine, densitometry

Healthcare Effectiveness Data and Information Set (HEDIS®)

Bisphosphonates	HCPCS	Formulary coverage	Prior authorization
Alendronate 5 mg, 10 mg, 35 mg and 70 mg tablets		T1	
Alendronate-cholecalciferol (Fosamax Plus D)		NF	
Ibandronate tablet		T2	
Ibandronate 3 mg/3 ml syringe and vial	J1740	T4	Yes
Pamidronate (30 mg/10 ml, 60 mg/10 ml, 90 mg/10 ml)		T3	
Risedronate tablet 5 mg, 30 mg, 35 mg and 150 mg, DR 35 mg		T3, DR 35 mg = T4	
Zoledronic acid 5 mg/100 ml	J3489	NF	Yes
Other agents	HCPCS	Formulary coverage	Prior authorization
Abaloparatide		T5	Yes
Calcitonin nasal spray		T3	
Denosumab (Prolia)	J0897	T4	
Denosumab (Xgeva)	J0897	T5	Yes
Raloxifene		T3	
Teriparatide (Forteo)	J3110	T5	Yes
Romosozumab (Evenity)	J3111	NF	

Based on 2025 Super National 5 MAPD

The coding information in this document is subject to changing requirements and should not be relied on as official coding or legal advice. All coding should be considered on a case-by-case basis and supported by medical necessity and appropriate documentation in the medical record.

The information offered in this flyer is based on Healthcare Effectiveness Data and Information Set (HEDIS®) technical specifications. It is not meant to preclude your clinical judgment.

The HEDIS measures and specifications were developed by and are owned by NCQA. The HEDIS measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures and specifications. NCQA holds a copyright in these materials and can rescind or alter these materials at any time. These materials may not be modified by anyone other than NCQA. Use of the Rules for Allowable Adjustments of HEDIS to make permitted adjustments of the materials does not constitute a modification. Any commercial use and/or internal or external reproduction, distribution and publication must be approved by NCQA and are subject to a license at the discretion of NCQA. Any use of the materials to identify records or calculate measure results, for example, requires a custom license and may necessitate certification pursuant to NCQA's Measure Certification Program. Reprinted with permission by NCQA. ©2025 NCQA, all rights reserved.

Limited proprietary coding is contained in the measure specifications for convenience. NCQA disclaims all liability for use or accuracy of any third-party code values contained in the specifications. The full text of this notice and disclaimer is available [here](#).